BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

414 related articles for article (PubMed ID: 29935372)

  • 1. Targeting the NRG1/HER3 pathway in tumor cells and cancer-associated fibroblasts with an anti-neuregulin 1 antibody inhibits tumor growth in pre-clinical models of pancreatic cancer.
    Ogier C; Colombo PE; Bousquet C; Canterel-Thouennon L; Sicard P; Garambois V; Thomas G; Gaborit N; Jarlier M; Pirot N; Pugnière M; Vie N; Gongora C; Martineau P; Robert B; Pèlegrin A; Chardès T; Larbouret C
    Cancer Lett; 2018 Sep; 432():227-236. PubMed ID: 29935372
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Cancer-Associated Fibroblasts in Pancreatic Ductal Adenocarcinoma Determine Response to SLC7A11 Inhibition.
    Sharbeen G; McCarroll JA; Akerman A; Kopecky C; Youkhana J; Kokkinos J; Holst J; Boyer C; Erkan M; Goldstein D; Timpson P; Cox TR; Pereira BA; Chitty JL; Fey SK; Najumudeen AK; Campbell AD; Sansom OJ; Ignacio RMC; Naim S; Liu J; Russia N; Lee J; Chou A; Johns A; Gill AJ; Gonzales-Aloy E; Gebski V; Guan YF; Pajic M; Turner N; Apte MV; Davis TP; Morton JP; Haghighi KS; Kasparian J; McLean BJ; Setargew YF; Phillips PA;
    Cancer Res; 2021 Jul; 81(13):3461-3479. PubMed ID: 33980655
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Neuregulin 1 Allosterically Enhances the Antitumor Effects of the Noncompeting Anti-HER3 Antibody 9F7-F11 by Increasing Its Binding to HER3.
    Le Clorennec C; Bazin H; Dubreuil O; Larbouret C; Ogier C; Lazrek Y; Garambois V; Poul MA; Mondon P; Barret JM; Mathis G; Prost JF; Pèlegrin A; Chardès T
    Mol Cancer Ther; 2017 Jul; 16(7):1312-1323. PubMed ID: 28507002
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Anti-metastatic potential of somatostatin analog SOM230: Indirect pharmacological targeting of pancreatic cancer-associated fibroblasts.
    Moatassim-Billah S; Duluc C; Samain R; Jean C; Perraud A; Decaup E; Cassant-Sourdy S; Bakri Y; Selves J; Schmid H; Martineau Y; Mathonnet M; Pyronnet S; Bousquet C
    Oncotarget; 2016 Jul; 7(27):41584-41598. PubMed ID: 27177087
    [TBL] [Abstract][Full Text] [Related]  

  • 5. An antibody that locks HER3 in the inactive conformation inhibits tumor growth driven by HER2 or neuregulin.
    Garner AP; Bialucha CU; Sprague ER; Garrett JT; Sheng Q; Li S; Sineshchekova O; Saxena P; Sutton CR; Chen D; Chen Y; Wang H; Liang J; Das R; Mosher R; Gu J; Huang A; Haubst N; Zehetmeier C; Haberl M; Elis W; Kunz C; Heidt AB; Herlihy K; Murtie J; Schuller A; Arteaga CL; Sellers WR; Ettenberg SA
    Cancer Res; 2013 Oct; 73(19):6024-35. PubMed ID: 23928993
    [TBL] [Abstract][Full Text] [Related]  

  • 6. IL1-Induced JAK/STAT Signaling Is Antagonized by TGFβ to Shape CAF Heterogeneity in Pancreatic Ductal Adenocarcinoma.
    Biffi G; Oni TE; Spielman B; Hao Y; Elyada E; Park Y; Preall J; Tuveson DA
    Cancer Discov; 2019 Feb; 9(2):282-301. PubMed ID: 30366930
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The Anti-HER3 mAb Seribantumab Effectively Inhibits Growth of Patient-Derived and Isogenic Cell Line and Xenograft Models with Oncogenic
    Odintsov I; Lui AJW; Sisso WJ; Gladstone E; Liu Z; Delasos L; Kurth RI; Sisso EM; Vojnic M; Khodos I; Mattar MS; de Stanchina E; Leland SM; Ladanyi M; Somwar R
    Clin Cancer Res; 2021 Jun; 27(11):3154-3166. PubMed ID: 33824166
    [TBL] [Abstract][Full Text] [Related]  

  • 8. RN1, a novel galectin-3 inhibitor, inhibits pancreatic cancer cell growth in vitro and in vivo via blocking galectin-3 associated signaling pathways.
    Zhang L; Wang P; Qin Y; Cong Q; Shao C; Du Z; Ni X; Li P; Ding K
    Oncogene; 2017 Mar; 36(9):1297-1308. PubMed ID: 27617577
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Stromal remodeling by the BET bromodomain inhibitor JQ1 suppresses the progression of human pancreatic cancer.
    Yamamoto K; Tateishi K; Kudo Y; Hoshikawa M; Tanaka M; Nakatsuka T; Fujiwara H; Miyabayashi K; Takahashi R; Tanaka Y; Ijichi H; Nakai Y; Isayama H; Morishita Y; Aoki T; Sakamoto Y; Hasegawa K; Kokudo N; Fukayama M; Koike K
    Oncotarget; 2016 Sep; 7(38):61469-61484. PubMed ID: 27528027
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Targeting ErbB3-mediated stromal-epithelial interactions in pancreatic ductal adenocarcinoma.
    Liles JS; Arnoletti JP; Kossenkov AV; Mikhaylina A; Frost AR; Kulesza P; Heslin MJ; Frolov A
    Br J Cancer; 2011 Aug; 105(4):523-33. PubMed ID: 21792199
    [TBL] [Abstract][Full Text] [Related]  

  • 11. HER3 Is an Actionable Target in Advanced Prostate Cancer.
    Gil V; Miranda S; Riisnaes R; Gurel B; D'Ambrosio M; Vasciaveo A; Crespo M; Ferreira A; Brina D; Troiani M; Sharp A; Sheehan B; Christova R; Seed G; Figueiredo I; Lambros M; Dolling D; Rekowski J; Alajati A; Clarke M; Pereira R; Flohr P; Fowler G; Boysen G; Sumanasuriya S; Bianchini D; Rescigno P; Aversa C; Tunariu N; Guo C; Paschalis A; Bertan C; Buroni L; Ning J; Carreira S; Workman P; Swain A; Califano A; Shen MM; Alimonti A; Neeb A; Welti J; Yuan W; de Bono J;
    Cancer Res; 2021 Dec; 81(24):6207-6218. PubMed ID: 34753775
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Cancer-associated fibroblasts promote M2 polarization of macrophages in pancreatic ductal adenocarcinoma.
    Zhang A; Qian Y; Ye Z; Chen H; Xie H; Zhou L; Shen Y; Zheng S
    Cancer Med; 2017 Feb; 6(2):463-470. PubMed ID: 28097809
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Pancreatic Tumor Microenvironment Factor Promotes Cancer Stemness via SPP1-CD44 Axis.
    Nallasamy P; Nimmakayala RK; Karmakar S; Leon F; Seshacharyulu P; Lakshmanan I; Rachagani S; Mallya K; Zhang C; Ly QP; Myers MS; Josh L; Grabow CE; Gautam SK; Kumar S; Lele SM; Jain M; Batra SK; Ponnusamy MP
    Gastroenterology; 2021 Dec; 161(6):1998-2013.e7. PubMed ID: 34418441
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Chemotherapy-Induced Inflammatory Gene Signature and Protumorigenic Phenotype in Pancreatic CAFs via Stress-Associated MAPK.
    Toste PA; Nguyen AH; Kadera BE; Duong M; Wu N; Gawlas I; Tran LM; Bikhchandani M; Li L; Patel SG; Dawson DW; Donahue TR
    Mol Cancer Res; 2016 May; 14(5):437-47. PubMed ID: 26979711
    [TBL] [Abstract][Full Text] [Related]  

  • 15. CXCR2 signaling promotes secretory cancer-associated fibroblasts in pancreatic ductal adenocarcinoma.
    Awaji M; Saxena S; Wu L; Prajapati DR; Purohit A; Varney ML; Kumar S; Rachagani S; Ly QP; Jain M; Batra SK; Singh RK
    FASEB J; 2020 Jul; 34(7):9405-9418. PubMed ID: 32453916
    [TBL] [Abstract][Full Text] [Related]  

  • 16. GPR68, a proton-sensing GPCR, mediates interaction of cancer-associated fibroblasts and cancer cells.
    Wiley SZ; Sriram K; Liang W; Chang SE; French R; McCann T; Sicklick J; Nishihara H; Lowy AM; Insel PA
    FASEB J; 2018 Mar; 32(3):1170-1183. PubMed ID: 29092903
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Tumor Microenvironment-Derived NRG1 Promotes Antiandrogen Resistance in Prostate Cancer.
    Zhang Z; Karthaus WR; Lee YS; Gao VR; Wu C; Russo JW; Liu M; Mota JM; Abida W; Linton E; Lee E; Barnes SD; Chen HA; Mao N; Wongvipat J; Choi D; Chen X; Zhao H; Manova-Todorova K; de Stanchina E; Taplin ME; Balk SP; Rathkopf DE; Gopalan A; Carver BS; Mu P; Jiang X; Watson PA; Sawyers CL
    Cancer Cell; 2020 Aug; 38(2):279-296.e9. PubMed ID: 32679108
    [TBL] [Abstract][Full Text] [Related]  

  • 18. MicroRNA-323-3p inhibits cell invasion and metastasis in pancreatic ductal adenocarcinoma via direct suppression of SMAD2 and SMAD3.
    Wang C; Liu P; Wu H; Cui P; Li Y; Liu Y; Liu Z; Gou S
    Oncotarget; 2016 Mar; 7(12):14912-24. PubMed ID: 26908446
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Functional genomic characterization of a synthetic anti-HER3 antibody reveals a role for ubiquitination by RNF41 in the anti-proliferative response.
    Turowec JP; Lau EWT; Wang X; Brown KR; Fellouse FA; Jawanda KK; Pan J; Moffat J; Sidhu SS
    J Biol Chem; 2019 Jan; 294(4):1396-1409. PubMed ID: 30523157
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Neoplastic-Stromal Cell Cross-talk Regulates Matrisome Expression in Pancreatic Cancer.
    Honselmann KC; Finetti P; Birnbaum DJ; Monsalve CS; Wellner UF; Begg SKS; Nakagawa A; Hank T; Li A; Goldsworthy MA; Sharma H; Bertucci F; Birnbaum D; Tai E; Ligorio M; Ting DT; Schilling O; Biniossek ML; Bronsert P; Ferrone CR; Keck T; Mino-Kenudson M; Lillemoe KD; Warshaw AL; Fernández-Del Castillo C; Liss AS
    Mol Cancer Res; 2020 Dec; 18(12):1889-1902. PubMed ID: 32873625
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 21.